Livzon is Always Committed to Human Healthcare
Livzon Pharmaceutical Group Inc., established in January 1985 with registered capital of 953 million yuan, is a comprehensive pharmaceutical group company integrating pharmaceutical R&D, production and sales, with more than 9,000 employees. In 1993, Livzon A and B shares have been listed. In 2014, the company completed the conversion from B shares to H shares, making it one of the few listed pharmaceutical companies with A+H shares in the capital market.
In 2018, the company has total assets of 17.4 billion yuan, annual operating revenue of 8.861 billion yuan, net profit of 1.18 billion yuan and R&D investment of 687 million yuan.
Livzon is committed to ensuring effective, safe and stable products. The Group's pharmaceutical enterprises have established a sound quality management system. As of 2018, Total 31 production lines of 4 pharmaceutical subsidiaries have passed GMP certification. 28 varieties of 4 API companies have passed GMP certification and other 11 varieties have passed veterinary medicine GMP certification. 15 API varieties have passed the field inspection of international certification and obtained 20 international certification certificates.
The company has more than 400 varieties of API, chemical drugs, proprietary Chinese medicines, biological drugs, biochemical drugs and diagnostic reagents, more than 90 varieties of which are produced and sold, involving digestive, cardio-cerebrovascular, reproductive endocrinology, psychotropic/neurological, anti-infectious, anti-tumor fields, etc. advanta
Among them, the blockbuster products in the digestive field are: Iylian (Ilaprazole Enteric-Coated Tablets/national class 1 new drug; Ilaprazole Sodium for Injection/national class 2 new drug), Livzon Dele Series (Bismuth Potassium Citrate Granules/Tablets/Capsules, Jindele (Bismuth Ranitidine Citrate Tablets) and Livzon combined package (Bismuth Potassium Citrate Tablets/Tinidazole Tablets/Clarithromycin Tablets), Rabeprazole, Livzon Changle (Live Bifidobacterium Capsules), and Limeilin (Domperidone Tablets)
The competitive products in gynecologyl/assisted reproductive technology are: Leuprorelin Acetate Microspheres for Injection, Lishenbao (Urofollitropin for Injection), Lebaode (Menotropin for Injection) and Chorionic Gonadotrophin for Injection.
The core products in the field of anti-infection are: Anti-viral Granules, Kanglineng (Cefodizime Sodium for Injection), Lifukang (Voriconazole for Injection), Lizhuwei (Valacyclovir Hydrochloride Tablets).
The key products in the psychotropic/neurological field are: Kangerting (Perospirone Hydrochloride Tablets), Ruibile (Fluvoxamine Maleate Tablets), Likangle (Mouse Nerve Growth Factor for Injection, national class 1 new drug);
The cardiovascular and cerebrovascular products are: Valsartan Capsules, Amlodipine Besylate Tablets, Xinnaolilong (Divitamins Notoginseng and Cinnarizine Capsules), Pravastatin Sodium Capsules, Isosorbide Mononitrate Tablets, and Xueshuantong Injection (indicated for dilating blood vessels and improving circulation, etc).
The competitive product for tumor is Shenqi Fuzheng Injection.
The market share of 15 API products in API filed ranks first in the world.
In recent years, the company has integrated R&D resources and increased its investment, which has built a R&D platform consisting of Livzon Research Institute, Livzon Microsphere company, Livzon Mabpharm, Livzon API R&D Center, Livzon Traditional Chinese Medicine Division R&D Center. It has 3 national R&D platforms: National Engineering and Technology Research Center for the Modernization of Traditional Chinese Medicine, National Certification Enterprise Technology Center, and National and Local Joint Engineering Research Center for the Long-term Microsphere Technology, and has 4 provincial R&D platforms in Guangdong province: Guangdong High-tech Enterprise, Guangdong Key Engineering Technology Research and Development Center, Guangdong Digital Traditional Chinese Medicine Engineering Technology Research and Development Center, and Guangdong Cephalosporin Pharmaceutical Engineering Technology Research Center.
The Livzon Research Institute achieved the second-level unit management in 2015, and has now become a comprehensive R&D institution with high level and multi-field R&D capability. The Research Building is the R&D base of the Institute. The Research Building covers an experimental area of 7,770 square meters, a pilot-test workshop area of over 1,000 square meters, and an office area of 1,350 square meters. There are more than 500 sets of equipment for analysis and testing, preparation research and pilot-scale enlargement research, with a total value of more than 40 million yuan. Related instruments are imported advanced equipment, including Type 905 automatic potentiometric titrator/polarimeter/aseptic isolator/ozone sterilizer/biosafety cabinet/bacteria collector HTY-602A/vertical pressure steam sterilizer..
Livzon Microsphere Technology Co. , Ltd was founded on July 3, 2017, and is one of the earliest enterprises to develop microsphere products in China. In January 2013, Livzon Group officially introduced the microsphere project platform and built the Microsphere Room of the Chemical Pharmaceuticals Research Laboratory inthe Research Institute. In March 2015, it was awarded the title of "National and Local Joint Engineering Research Center for the Long-term Microsphere Technology", and there are 6 projects under development.
In 2016, it won the "Pearl River Talent Plan" of Guangdong province and introduced the sixth batch of innovation and entrepreneurship team. In 2016-2017, it won the Special Project to Support Industrialization of Major Scientific and Technological Achievements in Guangdong province. In 2017, it won the National Special Project for the Innovation and Manufacture of Major New Drugs, etc. The listed product of the company -- Leuprorelin Acetate Microspheres for Injection, mainly for the treatment of endometriosis and uterine fibroids, is one of the earliest microsphere sustained-release preparations listed in China.
Livzon Mabpharm Inc. was founded in 2010 by Livzon Group and Joincare Pharmaceutical Group. Its main businesses cover R&D, tech transfer of bio-pharmaceutical products and antibody drugs with bio-innovative drugs as the core, and biosimilar drugs as the supplement. The Company has a world-class leadership team with first-class innovation and industrialization capabilities.
The company plans to apply for production for the first product (LZM003) in 2020, and after that, on average, at least one new product will apply for production every year, accelerating the R&D of the innovation medicines to make at least 2-3 new programs enter into the clinical phase each year, optimizing the European and American clinical report ability, improving the CAR-T R&D line, laying out the global innovation projects, expanding the independent production ability, to gradually achieve good business performance, and create substantial profits for shareholders and investors.
API R&D Center: The Livzon API R&D Division integrates automation, machine learning and genomics. and uses the genomics as a search engine to efficiently exploit the microbial potential. Synthetic biology combines microbial breeding as a tool to develop new API products and increase the yield of target strains. The R&D team established five major topics, covering bioinformatics, microbial strain improvement, fermentation optimization, peptide synthesis and API quality research. To date, more economical and reliable working strains (e.g. acarbose, lovastatin, oritavancin, etc.) have been successfully developed using the above genomics data and biological tools.
There are 4 pharmaceutical preparation production enterprises subordinate to Livzon, including Livzon (Group) Pharmaceutical Factory, located in Livzon Industrial Park, Zhuhai City, Guangdong Province, which is the leading chemical and biological drug production base in China; Shanghai Livzon Pharmaceutical Co., Ltd., located in Jinqiao Development Zone, Shanghai, which is a chemical and biochemical drug production base; Livzon (Group) Limin Pharmaceutical Factory, located in Shaoguan city, Guangdong province, which is a traditional Chinese medicine production base; Sichuan Guangda Pharmaceutical Co., Ltd., located in Chengdu city, Sichuan Province, which is a traditional Chinese medicine production base.
Established on June 26, 2015, headquartered in Livzon New North River Pharmaceutical Co., Ltd., in 1st Renmin Road, Qingyuan City, Guangdong Province, Livzon Group’s API Business Division is a headquarter enterprise integrating R&D, production and sales of APIs. Its subsidiaries include Livzon New North River Pharmaceutical Co., Ltd. (Qingyuan, Guangdong), Livzon Ningxia Pharmaceutical Co., Ltd. (Pingluo, Ningxia), Fuzhou Fuxing Pharmaceutical Co., Ltd. (Jiangyin of Fuzhou; Gutian of Ningde), Livzon Synthetic Pharmaceutical Co., Ltd. (Free Trade Zone, Zhuhai, Guangdong Province; Jiaozuo of Henan Province). At present, its output value exceeds 2 billion yuan, with nearly 3,000 employees. These subsidiaries are mainly engaged in the R&D, production and sales of human/animal APIs, pharmaceutical intermediates, food additives and other products.
Livzon Group is headquartered (Livzon Industrial Park) in Biomedical Industrial Park in Jinwan District, Zhuhai City, Guangdong Province, covering an area of more than 420,000 square meters, with an investment of more than 2 billion yuan. It was started to build in July 2008, the first phase of the project was officially put into operation in December 2010, and all the relocation was completed on November 28, 2016.
Livzon Industrial Park was designed by German IPI company and constructed in accordance with the standards of American FDA and European COS (European pharmacopoeia adaptability certification), in which advanced energy saving control technology has been adopted and zero emission has been achieved. The automatic entry and exit box freeze-dried powder injection production line, the fully automatic three-dimensional high rack warehouse and logistics system, the solid preparation workshop adopting the advanced process concept from abroad and other hardware facilities are all in the first-class level in China.
Livzon Diagnostics Inc., established in 1989, is a high-tech enterprise subordinate to Livzon Group specializing in the R&D, production and marketing of in vitro diagnostic reagents and instruments. With a sound production quality management system, it has passed the national GMP certification, GSP certification and German TÜV ISO13485/ISO9001 certification, where there are professional elites in multiple fields including laboratory medicine, biological engineering, etc. A number of technology platforms, such as ELISA, colloidal gold, chemiluminescence, clinical biochemistry, microbial and molecular detection have been successively set up, with strong multi-platform research and development capabilities. In addition, Livzon Diagnostics Inc. actively expands international cooperation and has established long-term friendly cooperation with world-class biomedical enterprises such as Alere of the United States, Fujirebio of Japan, MP of Singapore, Simens of Germany, etc. The product field covers hepatitis, AIDS, sexually transmitted diseases, eugenics, drug concentration monitoring, tumor marker monitoring and blood nucleic acid screening and other fields, for the purpose of achieving characteristic disease management detection of Livzon.
In recent years, Livzon Diagnostics Inc. has increased its investment in new technology platforms such as molecular nucleic acid detection and automation, chemiluminescence, liquid-phase chip multiple immunity, etc. In addition, a batch of new projects is being developed to further strengthen the product category and strength of the enterprise.
Livzon marketing headquarter has set up a nationwide distribution network of prescription drugs, and has built a marketing network and main business channels covering the national market throughout more than 400 cities in 31 provinces; An expert network of academic exchanges has been established for different therapeutic fields. The sales center of Livzon API Business Division has established a domestic and international sales network, among which 14 products including acarbose, tobramycin sulfate, Selamectin, Mibemycin Oxime, Moxidectin, Kara series products, Mevastatin, Lovastatin, mycophenolic acid, etc. have ranked top in the global market shares.
Mission, Goal, Vision
Our mission is to dedicate to the cause of human health!
Our goal is to provide domestic first-class and international leading specialty drugs!
Our responsibility is to revitalize the national pharmaceutical industry, and our vision is to become the world’s leading pharmaceutical enterprise!
At the new stage of development, Livzon takes “Make All to Zero, Start Business Again” as the overall development tone, to implement “three strategies” including talent strategy, product strategy and market strategy, put emphasis on the layout of “nine fields”, that is, the digestive tract field, microsphere and other high-end preparation field, monoclonal antibody field, psychotropic/neurological field, reproductive field, diabetes drug field with polypeptide biosimilars, traditional Chinese medicine field, API field and pet preparation field. With the entrepreneurial feelings to “stand on the shoulders of the giant to climb new heights, stand on the top of Mount Everest to expand new horizons", the company will achieve new breakthroughs in the overall operation.